| [1] |
Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011 [J]. Obes Surg, 2012, 22(5): 677-684.
|
| [2] |
Benaiges D, Goday A, Pedro-Botet J, et al. Bariatric surgery: to whom and when? [J]. Minerva Endocrinol, 2015, 40(2): 119-28.
|
| [3] |
English WJ, DeMaria EJ, Brethauer SA, et al. American Society for Metabolic and Bariatric Surgery estimation of metabolic and bariatric procedures performed in the United States in 2016 [J]. Surg Obes Relat Dis, 2018, 14(3): 259-63.
|
| [4] |
Kassir R, Debs T, Blanc P, et al. Complications of bariatric surgery: Presentation and emergency management [J]. Int J Surg, 2016, 2777-2781.
|
| [5] |
Machytka E, Gaur S, Chuttani R, et al. Elipse, the first procedureless gastric balloon for weight loss: a prospective, observational, open-label, multicenter study [J]. Endoscopy, 2017, 49(2): 154-160.
|
| [6] |
Sallet JA, Marchesini JB, Paiva DS, et al. Brazilian multicenter study of the intragastric balloon [J]. Obes Surg, 2004, 14(7): 991-998.
|
| [7] |
Ribeiro IB, Kotinda A, Sánchez-Luna SA, et al. Adverse Events and Complications with Intragastric Balloons: a Narrative Review (with Video) [J]. Obes Surg, 2021, 31(6): 2743-2752.
|
| [8] |
Genco A, Bruni T, Doldi SB, et al. BioEnterics Intragastric Balloon: The Italian Experience with 2, 515 Patients [J]. Obes Surg, 2005, 15(8): 1161-1164.
|
| [9] |
Taha O, Abdelaal M, Asklany A, et al. Outcomes of a Swallowable Intragastric Balloon (Elipse™) on 96 Overweight and Obese Patients [J]. Obes Surg, 2021, 31(3): 965-969.
|
| [10] |
Espinet Coll E, Carrasco Clavijos S, Díaz Galán P, et al. Feasibility, results and endoscopic requirements of the Elipse® swallowable intragastric balloon: initial experience [J]. Rev Esp Enferm Dig, 2019, 111(12): 921-926.
|
| [11] |
Jense MTF, Palm-Meinders IH, Sanders B, et al. The Swallowable Intragastric Balloon Combined with Lifestyle Coaching: Short-Term Results of a Safe and Effective Weight Loss Treatment for People Living with Overweight and Obesity [J]. Obes Surg, 2023, 33(6): 1668-1675.
|
| [12] |
Ienca R, Giardiello C, Scozzarro A, et al. Improving Nausea and Vomiting Post-Elipse Balloon: a Novel Single-Dose Regimen of 300 mg Netupitant/0.5 mg Palonosetron Hydrochloride [J]. Obes Surg, 2019, 29(9): 2952-2956.
|
| [13] |
Sullivan S, Swain J, Woodman G, et al. Randomized sham-controlled trial of the 6-month swallowable gas-filled intragastric balloon system for weight loss [J]. Surg Obes Relat Dis, 2018, 14(12): 1876-1889.
|
| [14] |
Moore RL, Seger MV, Garber SM, et al. Clinical safety and effectiveness of a swallowable gas-filled intragastric balloon system for weight loss: consecutively treated patients in the initial year of U.S. commercialization [J]. Surg Obes Relat Dis, 2019, 15(3): 417-423.
|
| [15] |
Vantanasiri K, Matar R, Beran A, et al. The Efficacy and Safety of a Procedureless Gastric Balloon for Weight Loss: a Systematic Review and Meta-Analysis [J]. Obes Surg, 2020, 30(9): 3341-3346.
|
| [16] |
Abu Dayyeh BK, Maselli DB, Rapaka B, et al. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial [J]. Lancet, 2021, 398(10315): 1965-1973.
|
| [17] |
Ienca R, Al Jarallah M, Caballero A, et al. The Procedureless Elipse Gastric Balloon Program: Multicenter Experience in 1770 Consecutive Patients [J]. Obes Surg, 2020, 30(9): 3354-3362.
|